Earnings Call · Q4 FY2024·2025-03-06

Q4 24EPS -32.26%·Rev n/aQ3 24EPS +30.77%·Rev n/aQ2 24EPS +12.12%·Rev n/aQ1 24EPS -100.00%*·Rev n/a⚠ consensus missing

Definium Therapeutics, Inc. DFTX

Stephanie Fagan — Investor Relations or Corporate Communications

Rob Barrow — Chief Executive Officer (CEO)

Dan Karlin — Chief Medical Officer (CMO)

+3.6%1d on move date+5.4% vs SPY3d−1.3%5d+1.1%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DFTX calls or request research access.

More DFTX calls Browse calls Request research access